The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Thirty-two-year-old Chen Wei-chi has been living with HIV since he was 18. Instead of letting it consume his life, he sought ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Officials in Brazil’s well-regarded public health system are scrambling to explain this week how six transplant patients ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...